+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease



Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease



Antimicrobial Agents and ChemoTherapy 63(6)



Isavuconazole, the active moiety of the prodrug isavuconazonium sulfate, has potent activity against a wide spectrum of fungal pathogens and is approved for the treatment of invasive aspergillosis, yet little is known about the tissue penetration of isavuconazole at the target sites of infection. Here, we explored the spatial and quantitative distribution of isavuconazole in tissue lesions in experimental pulmonary aspergillosis established in mice with chronic granulomatous disease (CGD) (gp91phox-). Matrix-assisted laser desorption ionization mass spectrometry imaging (MALDI-MSI) and laser capture microdissection (LCM)-directed high-pressure liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were used to analyze infected lungs and brain tissues collected 1, 3, 6, and 24 h after a single oral administration of the prodrug at a dose of 256 mg/kg of body weight (corresponding to 122.9 mg/kg of isavuconazole). Drug enrichment within granulomatous lesions was observed in lung tissue at 1 h postdose, although drug levels quickly equilibrated afterwards between lesion and nonlesion areas. A prominent antifungal effect in the infected lung tissue was revealed by histopathological analysis. Isavuconazole also penetrated into the brain with high efficiency. These data further support the value of isavuconazole to treat patients with invasive aspergillosis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066693980

Download citation: RISBibTeXText

PMID: 30988140

DOI: 10.1128/aac.00524-19


Related references

Invasive aspergillosis in chronic granulomatous disease. Medical Mycology 47 Suppl 1: S282-S290, 2009

Chronic granulomatous disease in an adult recognized by an invasive aspergillosis. American Journal of the Medical Sciences 343(2): 174-176, 2012

Invasive aspergillosis in chronic granulomatous disease: report of 7 cases. European Journal of Pediatrics 166(1): 83-84, 2006

Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and ChemoTherapy 61(9), 2017

Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: implications for clinical breakpoints. Journal of Antimicrobial ChemoTherapy 71(7): 1885-1891, 2017

Successful treatment with methylprednisolone pulse therapy for a life-threatening pulmonary insufficiency in a patient with chronic granulomatous disease following pulmonary invasive aspergillosis and Burkholderia cepacia infection. Respiration; International Review of Thoracic Diseases 66(6): 551-554, 1999

Treatment of invasive aspergillosis with itraconazole in a patient with chronic granulomatous disease. Journal of Infection 20(2): 147-150, 1990

Renal amyloidosis in a child with chronic granulomatous disease and invasive aspergillosis. Pediatric Nephrology 23(5): 831-834, 2008

Resistant invasive aspergillosis in an autosomal recessive chronic granulomatous disease. Fetal and Pediatric Pathology 32(4): 241-245, 2014

Nephrotic syndrome in a child with chronic granulomatous disease and invasive aspergillosis. Pediatric Nephrology 13(7): C59, Sept, 1999

Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. American Journal of Respiratory and Critical Care Medicine 157(5 Pt 1): 1694-1696, 1998

Granulocyte transfusions in children with chronic granulomatous disease and invasive aspergillosis. Therapeutic Apheresis and Dialysis 9(2): 137-141, 2005

Pharmacokinetics and Concentration-Dependent Efficacy of Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis. Antimicrobial Agents and ChemoTherapy 60(5): 2718-2726, 2017

Chronic granulomatous disease may be an underlying cause for invasive nocardiosis. Lung India 33(6): 703-704, 2016

Invasive pulmonary aspergillosis in an infant: an unusual presentation of chronic granulomatous disease. Pediatric Infectious Disease Journal 6(2): 215-217, 1987